LixiLan-L Study
Read about the efficacy and safety of Suliqua in this clinical summary of the phase III LixiLan-L study. This study demonstrates the efficacy of Suliqua a titratable fixed-ratio combination of insulin glargine + lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin.
Aroda VR, et al. Diabetes Care. 2016; 39: 1972–80
Always up to date?
Webinars, evidence, expert videos, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com. Prescribing information will be available at the meeting.